RNA editing with CRISPR-Cas13
Nucleic acid editing holds promise for treating genetic disease, particularly at the RNA level, where disease-relevant sequences can be rescued to yield functional protein products. Type VI CRISPR-Cas systems contain the programmable single-effector RNA-guided ribonuclease Cas13. We profiled type VI...
Main Authors: | , , , , , , |
---|---|
Other Authors: | , , , , , |
Format: | Article |
Language: | English |
Published: |
American Association for the Advancement of Science (AAAS),
2020-05-07T12:51:49Z.
|
Subjects: | |
Online Access: | Get fulltext |
Summary: | Nucleic acid editing holds promise for treating genetic disease, particularly at the RNA level, where disease-relevant sequences can be rescued to yield functional protein products. Type VI CRISPR-Cas systems contain the programmable single-effector RNA-guided ribonuclease Cas13. We profiled type VI systems in order to engineer a Cas13 ortholog capable of robust knockdown and demonstrated RNA editing by using catalytically inactive Cas13 (dCas13) to direct adenosine-to-inosine deaminase activity by ADAR2 (adenosine deaminase acting on RNA type 2) to transcripts in mammalian cells. This system, referred to as RNA Editing for Programmable A to I Replacement (REPAIR), which has no strict sequence constraints, can be used to edit full-length transcripts containing pathogenic mutations. We further engineered this system to create a high-specificity variant and minimized the system to facilitate viral delivery. REPAIR presents a promising RNA-editing platform with broad applicability for research, therapeutics, and biotechnology. National Institute of Allergy and Infectious Diseases (U.S.) (Grant R01AI117043) United States. Air Force. Office of Scientific Research (Grant FA9550-14-1-0060) National Institute of Mental Health (U.S.) (Grant 5DP1-MH100706) National Institute of Mental Health (U.S.) (Grant 1R01-MH110049) |
---|